Lilly’s shares were impacted after a difficult month for its weight loss drug, A recent study showed the pill form of Lilly's ...

Eli Lilly is a leader in the market for GLP-1 medicines. The company's Zepbound, indicated for weight loss, is racking up ...

Going up against these giants is no small challenge, but Viking is, so far, holding its own. And if it can play its cards ...

It's been around for 60 years, but the game of pickleball wasn't always the craze it is today. Dear Doc: I have a friend who ...

A restful night’s sleep is vital to a healthy lifestyle but an Indiana physician said most Americans are not getting enough ...

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Eli Lilly and Company (NYSE:LLY)’s pipeline has been advancing, thanks to positive study results in oncology and ...

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

It’s no secret that obesity is becoming an epidemic in the United  States. It’s estimated that by 2030, 50 percent of Americans will be obese. But the reality  is, it’s not just Americans.   According ...

Novo Nordisk said on Friday the U.S. Food and Drug Administration has granted accelerated approval for its weight-loss drug ...

It seems to be holding off on price adjustments demanded by President Trump.

"Forever" PFAS chemicals might hamper a teenager's ability to drop excess weight, even if they've undergone weight-loss ...